We’re excited to share a major update: Multiomic Health has identified novel patient endotypes and biomarkers for diabetic kidney disease (DKD)! These discoveries allow for precise patient segmentation and could significantly improve both clinical trial success rates and personalised care for DKD patients. Our CEO Robert Thong will present more on these findings at the LSX - partnering for Life Science eXecutives Investival Conference in London on November 18. #PrecisionMedicine #DiabeticKidneyDisease #AI
Multiomic Health’s Post
More Relevant Posts
-
Single-microglia #transcriptomic transition networks and real-world patient data to identify ketorolac as a repurposable therapy for #Alzheimer’s disease. A breakthrough in drug repurposing and precision medicine. #Genomics #DrugRepurposing #TranslationalMedicine #PrecisionMedicine” #ClevelandClinc
-
Following a successful #AAIC24, we’d like to share a blog post that we’ve published about new utilizations of biomarkers to improve Alzheimer’s disease (AD) diagnosis. Read it here: https://ow.ly/cZxv50SQ8pi #AlzheimersDisease #EndAlz
-
Just published! A new proof-of-concept study explores the potential involvement of Circulating Multiple Myeloma Cells (CMMCs), counted via CELLSEARCH®, in monitoring multiple myeloma (MM) and smouldering MM (SMM) disease dynamics by measuring them during treatment and correlating the results with the prognoses of the patients. The results show that CMMC counts in the MM patients are correlated with clinical–biochemical features and suggest that persistence of CMMC during therapy is potentially linked to poor prognosis. https://lnkd.in/dRV3t8MZ #MultipleMyeloma #CMMC #LiquidBiopsy #CELLSEARCH
-
I'm thrilled to share our recent publication in the Journal of Crohn's and Colitis, where we identified two shared molecular subtypes in Crohn’s Disease (CD) and Ulcerative Colitis (UC). This research is a step forward in understanding the diverse mechanisms underlying IBD. 🧬🔬 Key Insights: 1. Our analysis of 827 CD or UC samples across six datasets uncovered two shared subtypes and developed a 20-gene classifier. 2. Subtype S1, characterized by immune and tissue remodeling pathways, represents patients with more significant unmet medical needs, often non-responsive to current treatments like corticosteroids, infliximab, vedolizumab, and ustekinumab. 3. In contrast, Subtype S2 showed improved responses to these therapies, highlighting the potential for tailored treatment strategies. This work underscores the importance of personalized medicine and may lead to more effective interventions for those with the greatest unmet medical needs. 💡✨ 👉 Explore the full study: https://lnkd.in/euBRdSJf
-
Professor at the Department of Biomedical Science, University of Sassari
Hello everyone, I’m thrilled to share our latest publication on exosomes and cardiomyopathies. Exosomes, small extracellular vesicles vital for intercellular communication, show great promise in diagnosing and treating cardiomyopathies. Their role in diseases like dilated, restrictive, arrhythmogenic, and hypertrophic cardiomyopathy highlights their potential as both diagnostic biomarkers and therapeutic targets. A deeper understanding of how exosomes affect disease progression could lead to better diagnosis and treatment strategies, ultimately improving patient outcomes. However, further research is needed to unlock their full clinical potential. Check out our Open Access article published in Life Science through the link below! #exosomes #cardiomyopathies #diagnosis #biomarkers #treatment
-
Staff Clinician, Critical Care Medicine and Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
🧬 Thrilled to share our latest publication! Autoantibodies are essential in diagnosing autoimmune #InterstitialLungDisease, but conventional immunoassays have limitations. Our study shows how the luciferase immunoprecipitation system (LIPS) overcomes these by accurately measuring a broad range of autoantibodies. We analyzed myositis-specific autoantibodies—including MDA5, Jo-1, PL-7, PL-12, ZO, and KS—in patients with #Myositis, #Sjogrens, and healthy controls. Notably, LIPS quantified anti-Jo1 levels longitudinally in ILD patients, mirroring lung function improvements over time and underscoring their biomarker potential for treatment response. Read more in Frontiers in Immunology: https://lnkd.in/eFWe62ma #AutoimmuneDisease #Research #Proteomics #LungHealth
-
Grifols is piloting a program that utilizes high-tech analysis of blood plasma samples to identify biomarkers indicative of Parkinson's disease, potentially leading to earlier diagnoses. The pilot program is underway in collaboration with the Michael J. Fox Foundation for Parkinson's Research. Grifols’ plasma sample repository is one of the largest globally, with over 100 million samples collected over nearly 15 years. #healthtech #diagnostics #parkinsonsdisease https://lnkd.in/eEYQEu7M
-
Thrilled to announce our partnership with Scipher Medicine! Together we will transform the autoimmune space by combining the powerful clinical data of OMNY Health's national network with the rich genomic insights from PrismRA, a personalized blood test for #rheumatoidarthritis. Looking forward to this seeing this novel precision medicine collaboration fueling the development of more targeted therapies and improving overall patient outcomes for #autoimmune patients.
Scipher Medicine and OMNY Health today announced a partnership to advance precision medicine efforts for immunology. This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher with OMNY Health's vast EHR network that reaches more than 80 million patients. OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis (RA), which enables comprehensive tracking of patient outcomes and disease progression. This partnership unlocks a wealth of information for researchers and drug developers. By combining the detailed clinical data within OMNY Health's network with the rich genomic insights from PrismRA, a personalized blood test for RA, researchers may gain a holistic view of the patient journey. This deeper understanding will fuel the development of more targeted therapies and improve overall patient outcomes. #PrecisionMedicine #AutoimmuneDisease #RheumatoidArthritis #TargetedTherapy #RealWorldEvidence #ArtificialIntelligence https://lnkd.in/e825Xqp4
-
Scipher Medicine and OMNY Health today announced a partnership to advance precision medicine efforts for immunology. This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher with OMNY Health's vast EHR network that reaches more than 80 million patients. OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis (RA), which enables comprehensive tracking of patient outcomes and disease progression. This partnership unlocks a wealth of information for researchers and drug developers. By combining the detailed clinical data within OMNY Health's network with the rich genomic insights from PrismRA, a personalized blood test for RA, researchers may gain a holistic view of the patient journey. This deeper understanding will fuel the development of more targeted therapies and improve overall patient outcomes. #PrecisionMedicine #AutoimmuneDisease #RheumatoidArthritis #TargetedTherapy #RealWorldEvidence #ArtificialIntelligence https://lnkd.in/e825Xqp4
-
CEO and Co-Founder at Brainomix, the Award-Winning AI Enabled Precision Medicine Company
This landmark strategic partnership between Brainomix and Boehringer Ingelheim paves the way to transform the diagnosis and treatment of patients with fibrosing lung disease. If these patients are untreated, they have a life expectancy worse than cancer and yet despite this, they often have to wait up to 2 years for diagnosis. With our AI-powered imaging biomarkers in e-Lung, we are aiming to change this by bringing forward diagnosis decisions and giving access to treatments earlier, improving patient outcomes. It is through such partnerships that we have achieved clinical impact at scale in stroke and now our mission is to replicate this success in fibrosing lung disease. #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360 #BoehringerIngelheim
Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US. Michalis Papadakis: "There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and it can take many years for a patient to be diagnosed. "This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families." Read more about this partnership: ⬇ https://lnkd.in/eFhtvQhE Boehringer Ingelheim #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360
Pharmaceuticals Executive. Clinical Developer. Value-driven innovator. Builder of winning teams.
4moOne step closer to designing efficient trials, for the right type of patients. This is excellent news, not only for kidney disease trialists, but also for all patients suffering from #ChronicKidneyDisease with #T2D! Kudos, Multiomic Health team.